China NMPA Drug Inspection - Hubei Jurui Traditional Chinese Medicine Pieces Co., Ltd. - Uncaria rhynchophylla

On March 29, 2022, the Hubei Provincial Drug Administration released its first Drug Quality Bulletin of the year, detailing the results of random inspections across drug production, distribution, and medical use units. The report identifies 28 batches of drugs that failed to meet quality standards. Involved companies include Hubei Shenlongyuan Pharmaceutical Co., Ltd., Jianmin Group Yekaitai (Suizhou) Co., Ltd., and Hubei Fuguang Pharmaceutical Co., Ltd., among others. Main violations identified during testing included physical discrepancies such as weight variation and incorrect pH values, as well as more serious safety concerns like excessive sulfur dioxide residues and high mercury oxide limits. Several traditional Chinese medicine products failed identification tests and appearance standards, while pharmaceutical packaging materials were found to have excessive solvent residues. Regulatory enforcement is based on the Chinese Pharmacopoeia (2015 and 2020 editions) and National Pharmaceutical Packaging Material Standards. In response, the administration has ordered immediate control measures, including sealing, seizing, and recalling the non-compliant batches. Relevant departments are required to investigate the manufacturers and tracing drug sources, especially where counterfeiting is suspected. Cases involving potential criminal activity will be transferred to public security organs for prosecution.